+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
G

Actively Recruiting

Researchers are observing the safety and performance of Terumo Aortic endovascular grafts used to treat patients with aortic aneurysms and other related conditions during routine clinical practice. This global, multi-center registry collects real-world data to better understand outcomes after these devices have been approved and are in use. The study is open label and includes multiple groups based on the type of aneurysm or device implanted. Participants receive one of several types of Terumo Aortic endovascular stent-grafts, including Thoracic Relay stent grafts, Abdominal Anaconda or Treo grafts, custom fenestrated devices, and Iliac artery-specific implants. These devices are CE marked or custom-made and are implanted following standard clinical procedures. The registry tracks patients treated with these devices in usual care settings without altering treatment. During the study, participants will attend follow-up visits where researchers collect safety data, patient-reported outcomes, and health economic information. Key outcomes measured include aortic-related mortality within 30 days post-implant, technical success on the day of surgery, and composite clinical success and additional endpoints at one year. The registry aims to monitor long-term performance and safety of these grafts in real-world use, with participation lasting as determined by follow-up schedules.

Age: 18Years +All Genders
58 locations